Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216190 | 0.98 | LTA4H (0.79) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL3209561 | 0.98 | LTA4H (0.79) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL17372602 | 0.92 | LTA4H (0.70) | LTA4HKDM4ESMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2970873 | 0.91 | KDM4E (0.69) | LTA4HKDM4EALDH1A1BACE1L3MBTL1 | |
| SCHEMBL3206091 | 0.88 | KMT2A (0.68) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL14320388 | 0.86 | LTA4H (0.63) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL521854 | 0.86 | LTA4H (0.63) | LTA4HKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3209535 | 0.84 | KDM4E (0.62) | LTA4HKDM4ESMN1; SMN2HTTLMNA | |
| SCHEMBL14451861 | 0.83 | LTA4H (0.70) | LTA4HBACE1PTGS1PTGS2 | |
| SCHEMBL28142884 | 0.83 | LTA4H (0.59) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3755696-B1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3755696-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | Samumed, LLC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2019165192-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-08-29 | — | — | WO | disclosed |
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | JOHNSON SIGMOND G (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | GELLIBERT FRANCOISE JEANNE (FR) | 2004-05-20 | — | — | US | disclosed |
| EP-1363904-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511980-B2 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-28 | — | — | US | disclosed |
| WO-2002062787-A1 | PYRAZOLES AS TGF INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885KDM4E 3598/4885SMN1; SMN2 1601/4885 |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885KDM4E 3598/4885SMN1; SMN2 1601/4885 |
| US-20040097502-A1 | Pyrazoles as tgf inhibitors | TGFBR1, TGFBR2, TGFB1 | LTA4H 2772/4885KDM4E 3508/4885SMN1; SMN2 2674/4885 |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | LTA4H 2264/4885KDM4E 2241/4885SMN1; SMN2 2449/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885KDM4E 3598/4885SMN1; SMN2 1601/4885 |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | LTA4H 2663/4885KDM4E 1778/4885SMN1; SMN2 3080/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LTA4H 1373/4885KDM4E 1645/4885SMN1; SMN2 986/4885 |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | MLNR, NPY4R, GIPR | LTA4H 2168/4885KDM4E 1623/4885SMN1; SMN2 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.